SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05731518 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: SC0245
DRUG: Irinotecan

Sponsor

Biocity Biopharmaceutics Co., Ltd.